| Literature DB >> 34603792 |
Suliman Khan1, Mohammad Mahdi Nejadi Babadaei2, Anwarul Hasan3,4, Zehra Edis5,6, Farnoosh Attar7, Rabeea Siddique1, Qian Bai8, Majid Sharifi9,10,11, Mojtaba Falahati10.
Abstract
Background: Because enzymes can control several metabolic pathways and regulate the production of free radicals, their simultaneous use with nanoplatforms showing protective and combinational properties is of great interest in the development of therapeutic nano-based platforms. However, enzyme immobilization on nanomaterials is not straightforward due to the toxic and unpredictable properties of nanoparticles in medical practice. Aim of review: In fact, because of the ability to load enzymes on nano-based supports and increase their renewability, scientific groups have been tempted to create potential therapeutic enzymes in this field. Therefore, this study not only pays attention to the therapeutic and diagnostic applications of diseases by enzyme-nanoparticle (NP) bio-conjugate (abbreviated as: ENB), but also considers the importance of nanoplatforms used based on their toxicity, ease of application and lack of significant adverse effects on loaded enzymes. In the following, based on the published reports, we explained that the immobilization of enzymes on polymers, inorganic metal oxide and hybrid compounds provide hopes for potential use of ENBs in medical activities. Then, the use of ENBs in bioassay activities such as paper-based or wearing biosensors and lab-on-chip/microfluidic biosensors were evaluated. Finally, this review addresses the current challenges and future perspective of ENBs in biomedical applications. Key scientific concepts of review: This literature may provide useful information regarding the application of ENBs in biosensing and therapeutic platforms.Entities:
Keywords: Biosensing; Conjugate; Drug delivery; Enzyme Immobilization; Nanomaterial; Therapy
Mesh:
Substances:
Year: 2021 PMID: 34603792 PMCID: PMC8463903 DOI: 10.1016/j.jare.2021.01.012
Source DB: PubMed Journal: J Adv Res ISSN: 2090-1224 Impact factor: 10.479
Advantages and disadvantages of different enzyme immobilization techniques.
| Immobilization methods | Advantages | Disadvantages |
|---|---|---|
| Adsorption | Simple production, no need for functionalization of support, inexpensive, lack of conformational changes of the enzyme, high catalytic activity, Minor changes of the active site of the enzyme. | The formation of weak bonds with solid support, low stability and high leakage. |
| Entrapment/ Encapsulation | High stability, minimal conformational changes of the enzyme, continuous reaction, easy downstream process, co-immobilization of different enzymes. | Low apparent activity of the enzyme, limitation of mass transfer, low loading percent, complicated experimental process. |
| Covalent attachment | Lack of enzyme leaching, strong interaction with the solid support, high stability, high operational consistency. | Mobility limitation of enzymes, low enzyme activity, structural restriction, most complicated and expensive, use of toxic chemicals. |
| Cross-linking | Strong bonding, lack of enzyme leakage, reusable, low release rate, | Decrease in enzymatic activity, decrease in diffusion rate, transfer limitations |
Summary of hybrid nanoplatforms applied for enzymes immobilization.
| Nanoplatforms | Immobilization type | Binding group | Immobilize enzyme | Ref. |
|---|---|---|---|---|
| Graphene oxide-Fe3O4 | Covalent binding | –OH, C = O | Glucoamylase | |
| Cellulose-Polyacrylic acid | Covalent binding | –OH, COOH | Horseradish peroxidase | |
| Chitosan-Alginate | Entrapment | –NH2, –OH | Amyl glucosidase | |
| ZnO-SiO2 | Cross-linking | –OH | Horseradish peroxidase | |
| Silica-Lignin | Adsorption | –OH, C = O | glucose oxidase |
Therapeutic enzymes immobilized on nanomaterials.
| Enzyme | Nanomaterials | Application | Ref. |
|---|---|---|---|
| Bilirubin oxidase | Albumin aggregate | Treatment of neonatal jaundice | |
| Chymotrypsin | Magnetic | Pancreatic insufficiency | |
| Serine endopeptidase | Antithrombotic therapy | Thrombolytic activities | |
| Chymotrypsin | Electrospinning nanofibers | Pancreatic insufficiency | |
| Beta-Galactosidase | Magnetic | Lactose intolerance | |
| Tyrosinase | Treatment of melanoma cancer | Polylactic-acid nanocapsules | |
| Lysozyme | Antimicrobial therapies | Nanofiber mats | |
| Asparginase | PEGylated | Acute lymphoblastic leukemia | |
| Glucose-6-phosphate dehydrogenase | SiO2-based matrix | Jaundice |
Fig. 1(A): a; Endothelial targeted antioxidant NPs formation scheme by controlled precipitation, b; Binding of Ab-PAC to cultured endothelial cells. 125I- labeled PACs incubated with cells at 37 °C, rinsed, lysed and measured for radioactivity, c; Tissue distribution of intravenous injected PACs into mice after 30 min circulation time. Protection by endothelial-targeted catalase PACs from oxidative stress in vitro (d) and in vivo based on brochoalveolar lavage (BAL) protein (e-f) [105]. (B): a; transmission electron micrograph of DendGDP NPs, b; Release of Dox from the NPs in the absence or presence of cathepsin (50 U), c; near-infrared fluorescence images for CT26-bearing male nude BALB/c mice. Dox itself or Dox-conjugated dendrimer NPs (5 mg/kg) were injected into the tail vein of each mouse. The major organs were removed from each mouse 48 h after injection [108].
Fig. 2(A): a; Schematic representation of the glucose-sensitive insulin delivery system using glucose-sensitive BGNs, b; The glucose-sensitive insulin released from the MNs in vivo, c; Profiles of insulin release in different pH, d; SEM images of BGNs-GOx/CAT MNs, e; Profiles of blood glucose levels after Ins-BGNs-GOx/CAT MNs injection of insulin treated with diabetic rats, f; Fluorescence and bright-field histological of FITC-labeled insulin-loaded MNs attached on diabetes rats, g; Histological sections of spleen, lung, and kidney of diabetic rat after treated [130].
Paper-based enzymatic nanobiosensors.
| Enzyme | Nanostructure | Analyte | Method | Detection limit | Ref. |
|---|---|---|---|---|---|
| GOx | Tungsten disulfide nanosheets | Blood glucose | Colorimetric method | 2.9 µM | |
| GOx | MFe2O4 | Glucose in the urine | Colorimetric biosensing | 4.5 × 10-7 M | |
| Glucose | AuNPs | Dihydronicotinamide | Colorimetric readout | 12.5 µM | |
| HRP | AuNPs | Nucleic acid | Lateral flow strip | 0.3 pM | |
| Cholesterol | AgNPs | Cholesterol | Amperometric detection | 0.25 mg/dL | |
| Acetyl thiocholine esterase | AuNPs | acetylthiocholine | Colorimetric method | 0.5 µM | |
| Acetylcholinesterase | CNTs | nerve agents | Lateral flow strip | 0.02 nM |
Fig. 3A: a-b; Power outputs and polarization curves with varying concentration of glucose in artificial sweat; (a) 0.02 mg/mL (~100 µM); (b) 0.2 mg/mL (~1 mM), c; The glucose levels in sweat were monitored immediately 30 min after the beginning of the exercise [137]. B: (a) Schematic diagram of a wireless operation of the iontophoretic-sensing tattoo device for transdermal alcohol sensing. In the diagrams of the tattoo-base device, blue and red highlights show the active zones during iontophoresis and amperometric detection, respectively, b; Control experiments without drinking, c; Experiments with consumption of 12 oz of beer measured from two different human subjects, before and after drinking alcohol beverage [145]. C: a; Pictures demonstrating NFC between a sweat monitoring device and a smartphone to launch software for image capture and analysis, b; Results of stress distribution associated with the devices on phantom skin and respective optical images under bending with 5 cm radius, c; colorimetric detection reservoirs that enable determination of total water loss and concentrations of lactate, glucose, creatinine, pH, and chloride ions in sweat, d; images of two different types of sweat patches (small and large harvesting areas) applied to the lower back and volar forearm collected at various times during the study [148].